NO854403L - Toerrstoffer og stabile suspensjoner. - Google Patents

Toerrstoffer og stabile suspensjoner.

Info

Publication number
NO854403L
NO854403L NO854403A NO854403A NO854403L NO 854403 L NO854403 L NO 854403L NO 854403 A NO854403 A NO 854403A NO 854403 A NO854403 A NO 854403A NO 854403 L NO854403 L NO 854403L
Authority
NO
Norway
Prior art keywords
stable suspensions
dry materials
substances
suspensions
dry
Prior art date
Application number
NO854403A
Other languages
English (en)
Other versions
NO169324C (no
NO169324B (no
Inventor
Leo Geller
Peter Glanzmann
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO854403L publication Critical patent/NO854403L/no
Publication of NO169324B publication Critical patent/NO169324B/no
Publication of NO169324C publication Critical patent/NO169324C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
NO854403A 1984-11-06 1985-11-05 Fremgangsmaate til fremstilling av toerrstoffer oppnaadd vedlyofilisering og egnet til fremstilling av stabile suspensjoner NO169324C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH530584 1984-11-06

Publications (3)

Publication Number Publication Date
NO854403L true NO854403L (no) 1986-05-07
NO169324B NO169324B (no) 1992-03-02
NO169324C NO169324C (no) 1992-06-10

Family

ID=4291364

Family Applications (1)

Application Number Title Priority Date Filing Date
NO854403A NO169324C (no) 1984-11-06 1985-11-05 Fremgangsmaate til fremstilling av toerrstoffer oppnaadd vedlyofilisering og egnet til fremstilling av stabile suspensjoner

Country Status (26)

Country Link
US (1) US5002940A (no)
EP (2) EP0181287B1 (no)
JP (2) JPS61204118A (no)
KR (1) KR890000907B1 (no)
AT (2) ATE84718T1 (no)
AU (2) AU586988B2 (no)
CA (1) CA1249223A (no)
CY (2) CY1898A (no)
DD (1) DD244292A5 (no)
DE (2) DE3576650D1 (no)
DK (1) DK162510C (no)
ES (1) ES8701491A1 (no)
FI (1) FI85809C (no)
GR (1) GR852637B (no)
HK (2) HK101192A (no)
HU (1) HU195728B (no)
IE (2) IE63166B1 (no)
IL (1) IL76943A (no)
MX (1) MX9203371A (no)
NL (1) NL940015I2 (no)
NO (1) NO169324C (no)
NZ (2) NZ214069A (no)
PH (1) PH21673A (no)
PT (1) PT81429B (no)
SG (1) SG107192G (no)
ZA (1) ZA858481B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH673395A5 (no) * 1987-01-30 1990-03-15 Ciba Geigy Ag
MX9201782A (es) * 1991-04-19 1992-10-01 Sandoz Ag Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene.
CH683151A5 (de) * 1991-04-24 1994-01-31 Ciba Geigy Ag Antikonzeption bei weiblichen Primaten ohne Beeinflussung des menstruellen Zyklus.
AU1787800A (en) * 1998-12-08 2000-06-26 Phares Pharmaceutical Research N.V. Phospholipid compositions
GB2344520A (en) * 1998-12-08 2000-06-14 Phares Pharm Res Nv Pharmaceutical carriers comprising lipids and polymers
US6447806B1 (en) 1999-02-25 2002-09-10 Novartis Ag Pharmaceutical compositions comprised of stabilized peptide particles
US6487907B1 (en) * 1999-07-08 2002-12-03 California Institute Of Technology Microgyroscope with integrated vibratory element
US20050100608A1 (en) * 2003-02-21 2005-05-12 Watson Pharmaceuticals, Inc. Testosterone oral dosage formulations and associated methods
ITMI20032054A1 (it) 2003-10-22 2005-04-23 Monteres S R L Processo per la preparazione di sospensioni farmaceutiche da inalare.
CA2697160A1 (en) * 2007-08-21 2009-02-26 Harbor Biosciences, Inc. Stabilized therapeutic compositions and formulations
WO2019213286A1 (en) * 2018-05-02 2019-11-07 LifeMax Laboratories, Inc. Extended release suspension formulation of lurasidone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2068447A1 (en) * 1969-11-26 1971-08-27 Orsymonde Dehydrated pharmaceutical comps by - lyophilisation
LU77457A1 (no) * 1977-05-31 1979-01-19
US4235893A (en) * 1978-05-08 1980-11-25 Brodie Angela M Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis
US4391755A (en) * 1982-01-18 1983-07-05 E. R. Squibb & Sons, Inc. Steroid monohydrates, formulations containing same and method
JPS58206513A (ja) * 1982-05-28 1983-12-01 Eisai Co Ltd セクレチン吸着防止組成物および方法
DE3225706C2 (de) * 1982-07-09 1984-04-26 A. Nattermann & Cie GmbH, 5000 Köln Flüssige Wirkstofformulierungen in Form von Konzentraten für Mikroemulsionen
DE3339295A1 (de) * 1982-11-15 1984-05-17 Schering AG, 1000 Berlin und 4709 Bergkamen 4-hydroxy- und 4-acyloxy-4-androsten-3,17-dione zur verwendung bei der prophylaxe und therapie der prostatahyperplasie und diese enthaltende mittel fuer derartige verwendung
DK79184A (da) * 1983-02-23 1984-08-24 Sanofi Sa Fungicide farmaceutiske midler indeholdende et imidazolderivat
EP0226021A1 (de) * 1985-12-12 1987-06-24 BBC Brown Boveri AG Thyristor mit schaltbarem Emitter-Kurzschluss

Also Published As

Publication number Publication date
IE852755L (en) 1986-05-06
DE3587020D1 (de) 1993-03-04
NZ214069A (en) 1989-08-29
JPH0558410B2 (no) 1993-08-26
DE3576650D1 (de) 1990-04-26
NZ229276A (en) 1989-08-29
EP0181287A2 (de) 1986-05-14
IE63156B1 (en) 1995-03-22
ZA858481B (en) 1986-06-25
IE902490L (en) 1986-05-06
NO169324C (no) 1992-06-10
AU4150489A (en) 1990-01-04
GR852637B (no) 1986-03-04
JPH0768130B2 (ja) 1995-07-26
CA1249223A (en) 1989-01-24
MX9203371A (es) 1992-09-01
FI854330A (fi) 1986-05-07
CY1677A (en) 1993-10-10
EP0346953A2 (de) 1989-12-20
CY1898A (en) 1985-10-31
NL940015I2 (nl) 1997-01-06
EP0346953B1 (de) 1993-01-20
KR890000907B1 (ko) 1989-04-13
ES548492A0 (es) 1986-12-01
PH21673A (en) 1988-01-13
IL76943A (en) 1990-02-09
EP0181287A3 (en) 1987-09-23
DK162510B (da) 1991-11-11
EP0346953A3 (en) 1990-11-22
ATE84718T1 (de) 1993-02-15
NL940015I1 (nl) 1994-10-17
HUT42936A (en) 1987-09-28
AU633844B2 (en) 1993-02-11
DK162510C (da) 1992-03-30
FI85809B (fi) 1992-02-28
AU4934485A (en) 1986-05-15
ES8701491A1 (es) 1986-12-01
FI854330A0 (fi) 1985-11-04
NO169324B (no) 1992-03-02
PT81429A (en) 1985-12-01
US5002940A (en) 1991-03-26
ATE51152T1 (de) 1990-04-15
DK509485D0 (da) 1985-11-05
DK509485A (da) 1986-05-07
IE63166B1 (en) 1995-03-22
JPH0648945A (ja) 1994-02-22
PT81429B (pt) 1988-03-03
AU586988B2 (en) 1989-08-03
DD244292A5 (de) 1987-04-01
KR860003825A (ko) 1986-06-13
HK101192A (en) 1992-12-24
HK192095A (en) 1995-12-29
JPS61204118A (ja) 1986-09-10
SG107192G (en) 1992-12-24
EP0181287B1 (de) 1990-03-21
HU195728B (en) 1988-07-28
FI85809C (fi) 1992-06-10

Similar Documents

Publication Publication Date Title
FI861674A (fi) Sukralfatsuspension.
NO854403L (no) Toerrstoffer og stabile suspensjoner.
DE3767400D1 (de) Biozide zusammensetzungen und deren verwendung.
AR240813A1 (es) N-fenilsulfonil-n'-pirimidinilureas, procedimiento para su preparacion, composiciones que las contienen e intermediarios para uso exclusivo en dicho procedimiento
GB2095260B (en) Ubstance and immunoactive composition biologically active substance process for preparing the s0
PT78713A (en) Dermatological compositions containing anthralin with improved stability
ES498864A0 (es) Perfeccionamientos en la preparacion de composiciones termo-genas
DE3583015D1 (de) Phospholipidkonjugate und deren herstellung.
SE8503513L (sv) Farmaceutiska och kosmetiska kompositioner, vilka som verksam bestandsdel innehaller acetyl-10-triacetoxi-1,8,9-antracen
DK50486A (da) Stangmaterialetransportoer
SE8400181D0 (sv) Kompositmaterial for formgods

Legal Events

Date Code Title Description
MK1K Patent expired